FDA Rejects Sotagliflozin As Insulin Add-On | Docwire News
The FDA rejected a new drug application for sotagliflozin (Zynquista) for use as an add-on to insulin therapy for glycemic control in adults with type 1 diabetes and CKD.
Related Articles
Greenland, oil and ‘all hell’ in the Middle East: Takeaways from Trump’s Mar-a-Lago press conference
From a new era of American imperialism to an enduring bitterness toward a criminal justice system he maintains unfairly targeted him, here are our top…
Two Iconic Malibu Restaurants Have Been Destroyed by the Palisades Wildfire
Reel Inn and Cholada Thai were reportedly destroyed by the fast-growing fire on January 7, 2025
Prolonged sauna exposure without adequate hydration linked to heat stroke risk
Basking too long in a sauna may put bathers at risk of heat stroke, particularly if they haven’t drunk enough water beforehand, warn doctors in…
Femoral or Radial Secondary Access in TAVR: A Subanalysis From the Multicenter PULSE Registry
AbstractBackgroundTransradial secondary access (TR-SA) may serve as an alternative to the traditional femoral secondary access (TF-SA) for pigtail placement in transcatheter aortic valve replacemen…
Novel JAK2 Inhibitor for Polycythemia Vera Receives Orphan Drug Designation | Blood Cancers Today
The FDA has granted the Orphan Drug Designation to VGT-1849A, a novel JAK2 inhibitor for the treatment of patients with polycythemia vera.
Special Collection : Obesity | JACC
Advances in obesity medicine are reshaping the science and practice of cardiology. JACC’s new comprehensive hub highlights the latest research, commentary, and multimedia, including a…
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths: An Analysis From the SELECT Trial
AbstractBackgroundPatients with overweight and obesity are at increased risk of death from multiple causes, including cardiovascular (CV) death, with few therapies proven to reduce the…
Semaglutide Improves Cardiovascular Outcomes in Patients With History of Coronary Artery Bypass Graft and Obesity:
Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael’s Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada ∗Address for correspondence:…
Updates from the SELECT Trial: Outcomes by Sex | ESC 2024
Neha J. Pagidipati, MD, FACC, JACC Associate Editor and Subodh Verma MD, PhD explore a secondary analysis of the SELECT trial, a landmark study investigating…
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT): Outcomes by Sex
St Michael’s Hospital and University of Toronto, Toronto, Ontario, Canada ∗Address for correspondence: Dr Subodh Verma, St Michael’s Hospital, 30 Bond Street, University of Toronto,…